Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Data are based on the full analysis set
The caveat: semaglutide has a longer track record and the SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events in patients with obesity and established cardiovascular disease data that doesnt yet exist for tirzepatide
Others need more time at each tier
[5] [6] Any UK use would involve an imported unlicensed medicine supplied on a named-patient basis, a route distinct from a manufacturer's 'specials' licence
use only if benefit outweighs risk 6
US$ 25.99
US$ 21.67
US$ 28.09
US$ 28.89
US$ 21.71
